News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arakis Ltd. Commences Phase IIb Trial Ror RA Drug


10/19/2005 5:09:12 PM

Arakis (Sosei) has commenced a Phase IIb dose-ranging study of AD 452, a novel, small-molecule, disease-modifying antirheumatic drug, designed to reduce joint inflammation and destruction, pain and preserve mobility.

Read at InPharm.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES